Scholarlink

<p>B-cell maturation antigen (BCMA)-targeted positron emission tomography/computed tomography (PET/CT) represents a promising tool for the management of multiple myeloma, enabling noninvasive and quantitative evaluation across different disease stages. This novel technique specifically addresses two major diagnostic challenges: the limited specificity of conventional <sup>18</sup>F-FDG PET/CT and the focal sampling constraints of bone marrow biopsies. In this prospective study, a <sup>68</sup>Ga-labeled nanobody-based BCMA tracer demonstrated improved detection compared with <sup>18</sup>F-FDG PET/CT, effectively visualizing para-medullary, extra-medullary and medullary lesions, as well as minimal residual disease (MRD). The tracer also reflected dynamic changes in BCMA expression associated with treatment response, underscoring its potential utility for guiding BCMA-targeted interventions, particularly in the era of chimeric antigen receptor T-cell (CAR-T) treatment. These preliminary findings support the potential of BCMA immunoPET as a comprehensive, noninvasive modality for MM evaluation and warrant validation in larger, prospective clinical trials.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

B-cell maturation antigen targeted PET/CT imaging in multiple myeloma: a first-in-human study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月14日

查看全文
  • Tingfei Gu,
  • Zhao Chen,
  • Tianyao Wang,
  • Yujun Dong,
  • Lei Kang

摘要

B-cell maturation antigen (BCMA)-targeted positron emission tomography/computed tomography (PET/CT) represents a promising tool for the management of multiple myeloma, enabling noninvasive and quantitative evaluation across different disease stages. This novel technique specifically addresses two major diagnostic challenges: the limited specificity of conventional 18F-FDG PET/CT and the focal sampling constraints of bone marrow biopsies. In this prospective study, a 68Ga-labeled nanobody-based BCMA tracer demonstrated improved detection compared with 18F-FDG PET/CT, effectively visualizing para-medullary, extra-medullary and medullary lesions, as well as minimal residual disease (MRD). The tracer also reflected dynamic changes in BCMA expression associated with treatment response, underscoring its potential utility for guiding BCMA-targeted interventions, particularly in the era of chimeric antigen receptor T-cell (CAR-T) treatment. These preliminary findings support the potential of BCMA immunoPET as a comprehensive, noninvasive modality for MM evaluation and warrant validation in larger, prospective clinical trials.